Clinical study of a combined use of Gefitinib and autologous lymphocyte-activated killer cells (LAK) therapy for advanced non-small cell lung cancer.

Clinical study of a combined use of Gefitinib and autologous lymphocyte-activated killer cells (LAK) therapy for advanced non-small cell lung cancer. - Clinical study of a combined use of Gefitinib and autologous lymphocyte-activated killer cells (LAK) therapy for advanced non-small cell lung cancer.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000000637

Enrollment

Registered

2007-03-16

Start date

2007-02-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

non-small cell lung cancer

Interventions

Autologous Lymphocyte-Activated Killer cells (LAK) Gefitinib

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients who are aged 20-80 years ; who are judged SD for Gefitinib therapy based on RECIST; who have no serious abnormality in bone marrow, liver and/or renal functions, and whose PS is 0-1 ; whose life-expectancy is more than 6 months.

Exclusion criteria

Exclusion criteria: Patients who have: previous history of hypersensitivity to Gefitinib, uncontrolled infections, active autoimmune diseases, and serious cardiac disease; who have received continuous systemic steroids; who are pregnant, to be pregnant, or nursing mothers, and whom principle investigator or co-investigator judged to be inappropriate to participate in this study.

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Secondary

Measure	Time frame
Survival rate Progression-free survival Antitumor effect Improvement of tumor-related markers QOL(FACT-BRM) Safety	—

Countries

Japan

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026